QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Radient Pharmaceuticals Corp. (RPC) Appoints Seasoned Director to Head North American Sales 0 comments
    Aug 12, 2010 3:28 PM | about stocks: RXPC

    Radient Pharmaceuticals Corp. focuses on developing and commercializing diagnostic tests that assist physicians in answering important clinical questions related to early disease detection, including its Onko-Sure® In Vitro Diagnostic (IVD) cancer test.

    The company today announced it has appointed Gary Giarrantano as director of North American Sales for the company where he will be responsible for managing the company’s sales and marketing strategy, operations and Onko-Sure(NYSE:R) IVD product sales.

    Giarratano has more than 20 years of healthcare, sales and marketing leadership experience. He is recognized for his contributions in new market development for Carcinoembryonic Antigen (NYSE:CEA), Prostate-Specific Antigen (NYSE:PSA) and Human Papillomavirus (HPV), and led sales for the first company to secure U.S. FDA approval on each of these assays.

    Giarratano’s sales experience includes positions with established and emerging healthcare and pharmaceutical companies, including Qiagen, Roche Diagnostics, AutoGenomics Inc., Sebia Inc., Esoterix Laboratory, PerkinElmer Life Sciences and Hybritech Inc.

    Radient said that Giarratano’s proven track record in the industry makes the company confidant he can increase the market reach of Onko-Sure.

    “Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,” Douglas MacLellan, chairman and CEO of Radient stated in the press release. “Giarratano has demonstrated talent in strategically aligning sales objectives with marketplace demands, and meeting those demands through proven sales performance. His wealth of expertise in the IVD industry combined with a proven ability to deliver results makes him an exceptional leader we believe will help propel sales of Onko-Sure to the next level.”

    Giarratano has established key professional relationships with major healthcare companies such as Quest, Lab Corp., Mayo, Kaiser, MetroPath, UniPath, Summit Pathology, TriCore, Intermountain Health Care and other regional reference labs.

    For more information visit radient-pharma.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Disclosure: no positions

    Stocks: RXPC
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.